Private stock company Advent International has signed a definitive investment agreement $ 175 million (o £1 500 crore) for a significant minority share in Felix Pharmaceuticals PVT. LTD, based in Ireland, focused on the development and production of generic medicines for social animals such as dogs, cats and horses.
This means another Advent bet in the growing medical space, this time by clicking the segment of animal health, where branded drugs continue to dominate.
Felix Pharma, founded in 2015, is one of the fastest growing companies in the animal health, with 14 USFDA products and several others in the pipeline. The company primarily supplies distributors and other branded gearbox players, especially in the US, through private labeling.
A large bet on an animal generics
“Felix has the opportunity to shape the Companion Animal Health Generics market. The industry is a nascent, with less than 10% of generic players, providing a long -term growth opportunity,” said Pankaj Patwari, CEO of Advent.
Mint earlier in February 2025 that Felix was investigating the sale of a share of Generics, Felix Generics.
“When we scared on a rapidly developing market, we were looking for a partner that brings not only capital but also deep operational knowledge and right thinking and networks that help us grow faster and stronger,” said Neer Agrawal, co -founder of Felix.
“Advent is strong results in health and pharmaceuticals and their close involvement in the building of strong businesses, give us great confidence,” he added.
Felix was co -founded by Neera Agrawal, McKinsey Kamenec, Sir Jonathan Symonds, GSK Chairman, and Dr. Shumeet Banerji, former CEO of Booz Allen Hamilton. The company received its first USFDA approval in 2020 and is now operating a specialized Center for Research and Development and a production plant approved by USFDA for animal health products.
Also read: Cognizant wins an agreement of $ 1 billion from the US medical company
The device includes dedicated solid solids and liquids adapted specifically to the veterinary generics market.
“For us, health care was a long -term focus and strong parallels that we see among the success in the human GX (Generics) globally and emerging opportunities in the animal’s health,” said Shweta Jala, head of the partner of Advent.
“Felix is fine to lead this space with its strong leadership, wide portfolio and robust research and development and commercial abilities,” she said.
The agreement comes in the middle of a sharp increase in global demand for animal drugs, because ownership of domestic animals and health care for pets across geographies.
Also read: These startups attract investors’ interest in the middle of the growing tribe of parents
Advent actively invests in Indian health and financial services. In April 2024 gained a 12.1% stake in Apollo Healthco, Apollo Hospital Unit, for £2 475 crore. Last year he invested $ 230 million in the microfin of the DVANTRA along with multiples of PE and left the serum and vaccines Bharat and sold it to humanity Pharma Pro £13 630 crore.
(Tagstotranslate) Advent International (T) Felix Pharma (T) Animal Health (T) Generic Medicines (T) Private Capital (T) PET Pharma (T) USFDA (T) Neer Agrawal (T) Shwet Jalan (T)
